Latest Commercialisation News

TALi Digital has successfully raised $800,000 through a private placement to fuel the commercialisation of its digital health products aimed at enhancing childhood cognitive attention.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.

Lithium Universe has acquired exclusive global rights to a pioneering microwave-based solar panel recycling technology from Macquarie University, aiming to revolutionize critical metal recovery and sustainability in the solar industry.

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.

Bass Oil Limited reported steady oil production in May with a 3% increase in output and announced plans to acquire the Vanessa gas field, marking a strategic pivot towards gas production in Australia’s evolving energy landscape.

Lakes Blue Energy NL has secured $6.5 million through a fully underwritten placement to fund drilling at its Wombat Gas Field in Victoria, aiming to address looming gas supply shortages on Australia's east coast.

EBR Systems has successfully completed a heavily oversubscribed Security Purchase Plan, raising a total of A$75.9 million alongside a prior institutional placement to fund its innovative wireless cardiac pacing technology through 2027.

Hazer Group Limited has opened a $2 million underwritten Share Purchase Plan, offering eligible shareholders in Australia and New Zealand the chance to buy shares at the same price as a recent institutional placement. The funds will support the commercialisation of its methane reactor technology and synthetic graphite development.

Provaris Energy and Yinson have completed the design of a groundbreaking large-scale liquid CO2 tank for maritime use and are forming a joint venture to commercialize this innovation, aiming to scale carbon capture supply chains and reduce costs.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

Beetaloo Energy has begun hydraulic stimulation on its record-length Carpentaria-5H well in the Beetaloo Basin, aiming to unlock enhanced gas production with advanced techniques. Results from the upcoming production test will be pivotal for the company’s pilot project and future development plans.

Clarity Pharmaceuticals has partnered with SpectronRx to manufacture and distribute its lead prostate cancer diagnostic, Cu-64 SAR-bisPSMA, at commercial scale across the US. This agreement sets the stage for a seamless launch pending FDA approval.